Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth factor receptor 2-targeted dual-payload antibody-drug conjugate ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC, and Callio’s ...
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing ...
Biotech-focused investment firm Frazier Life Sciences has launched Callio Therapeutics, a cancer treatment startup with headquarters in Seattle and Singapore. Frazier led a $187 million Series A round ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is focused on cancer ...
SEATTLE and SINGAPORE, March 3, 2025 /PRNewswire/ -- Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results